[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

UCLA Jonsson Comp Cancer Center, Los Angeles, California, United States
Contact: Study coordinator (Bhavisha Tailor) · BTailor@mednet.ucla.edu
Contact: Principal Investigator (Aditya Bardia)
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Contact: Study coordinator (Beth Thomsen) · beth.thomsen@hoag.org
Contact: Principal Investigator (Gary Ulaner)
University of Kansas Medical Center, Westwood, Kansas, United States
Contact: Study coordinator (Jordan Rarden) · jrarden@kumc.edu · 913-588-6030
Contact: Principal Investigator (Yiduo Hu)
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Erin Schubert) · erin.schubert@pennmedicine.upenn.edu · 215-573-6693
Contact: Principal Investigator (Neil Taunk)
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Afolashade O Bambe) · AOBambe@mdanderson.org
Contact: Principal Investigator (Senthilkumar Damodaran)
Utah Intermountain Medical Center, Murray, Utah, United States
Contact: Study coordinator (Becky Arroyo) · becky.arroyo@imail.org · 801-507-9333
Contact: Principal Investigator (Dustin Boothe)
Novartis Investigative Site, Guangzhou, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Tianjin, China
Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France
Novartis Investigative Site, Bordeaux, France
Novartis Investigative Site, Clermont-Ferrand, France
Novartis Investigative Site, Saint-Herblain, France
Novartis Investigative Site, Strasbourg, France
Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site, Erlangen, Germany
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, München, Germany
Novartis Investigative Site, Gliwice, Poland
Novartis Investigative Site, Porto, Portugal
Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain

Study leads

Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals

View source on ClinicalTrials.gov Contact study team (email)